#United States #SEC #DJS Law Group #Eastchester #Unicycive Therapeutics

Class Action Lawsuit Against Unicycive Therapeutics

On October 13, 2025, DJS Law Group announced the initiation of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for alleged securities law violations, specifically under §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. This legal action arises from claims that Unicycive misled investors regarding the approval prospects of its treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis.

Background of the Case

The lawsuit highlights the period from March 29, 2024 to June 27, 2025 as critical for affected investors. During this time, Unicycive reportedly made overly optimistic statements about the likelihood of receiving FDA approval for its drug candidate, known as OLC. The allegations suggest these public statements were materially misleading and contributed to significant investor losses as the company did not deliver on its promises regarding the approval process.

Investors who bought shares during this period may have experienced tangible financial damages due to the company's actions and statements. The DJS Law Group encourages shareholders to participate in the case, asserting that even those who do not seek to be lead plaintiffs may still qualify for recovery under the class action framework.

How to Participate

As part of the lawsuit process, shareholders who believe they were impacted can directly contact DJS Law Group for guidance. By registering as a participant, investors will receive ongoing updates regarding the case's status through sophisticated portfolio monitoring systems. DJS Law Group emphasizes that there are no costs or obligations associated with this registration, making it accessible to those looking to seek justice for their losses.

Why Choose DJS Law Group?

DJS Law Group prides itself on its commitment to enhancing investor returns through strategic legal guidance and vigorous advocacy. With a specialization in securities class actions and corporate governance cases, amongst others, the firm is well-equipped to tackle the complexities surrounding such legal matters. Their clientele includes some of the most prominent hedge funds and alternative asset managers, underscoring their credibility in the field.

In light of the lawsuit against Unicycive Therapeutics, individuals who have suffered financial setbacks are encouraged to consider participating in pursuing legal action. The potential for recovery in such cases is significant, and with DJS Law Group's expertise, affected parties may achieve satisfactory results.

Next Steps for Investors

Investors who meet the criteria to be part of the class action must act swiftly, as the deadline for joining is set for October 14, 2025. To ensure they have the best chance of maximizing their claims, individuals should not delay in reaching out to legal support from firms like DJS Law Group.

This class action serves not only as a means for individual investors to seek repair for losses but also emphasizes the importance of transparency and accountability in the corporate sector. As with any legal proceeding, the unfolding of this case will be closely monitored by both investors and the financial community at large, translating into broader discussions about corporate ethics and investor rights moving forward.

For affected shareholders seeking to recover their losses associated with Unicycive Therapeutics, contacting DJS Law Group could be a pivotal step in reclaiming financial stability.

For further details, interested parties can contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]